3-(BOC-氨基)吡啶甲酸甲酯 | 912369-42-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 3-(BOC-氨基)吡啶甲酸甲酯
• 英文名称: methyl 3-{[(tert-butoxy)carbonyl]amino}pyridine-2-carboxylate
• 英文别名: Methyl 3-((tert-butoxycarbonyl)amino)picolinate；methyl 3-[(2-methylpropan-2-yl)oxycarbonylamino]pyridine-2-carboxylate
• CAS: 912369-42-7
• 化学式: C₁₂H₁₆N₂O₄
• 分子量: 252.27
• InChiKey: AWHQAUKVCWXFSV-UHFFFAOYSA-N

物化性质

• 熔点：
  94 °C(Solv: hexane (110-54-3))
• 沸点：
  339.9±27.0 °C(Predicted)
• 密度：
  1.203±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  77.5
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335
• 储存条件：
  存储条件：2-8°C，建议使用惰性气体保护。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl 3-(BOC-amino)picolinate
Synonyms: Methyl 3-(tert-butoxycarbonylamino)picolinate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl 3-(BOC-amino)picolinate
CAS number: 912369-42-7

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C12H16N2O4
Molecular weight: 252.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-(BOC-氨基)吡啶甲酸甲酯 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3-氨基吡啶-2-羧酸甲酯
  参考文献：
  名称：

  Synthesis and Antiviral Activity of 7-Benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV Integrase Inhibitors

  摘要：

  The medicinal chemistry and structure-activity relationships for a novel series of 7-benzyl-4-hydroxy-1,5-naphthyridin-2(1H)-one HIV-integrase inhibitors are disclosed. Substituent effects were evaluated at the N-1, C-3, and 7-benzyl positions of the naphthyridinone ring system. Low nanomolar IC50 values were achieved in an HIV-integrase strand transfer assay with both carboxylic ester and carboxamide groups at C-3. More importantly, several carboxamide congeners showed potent antiviral activity in cellular assays. A 7-benzyl substituent was found to be critical for potent enzyme inhibition, and an N-(2-methoxyethyl)-carboxamide moiety at C-3 significantly reduced plasma protein binding effects in vitro. Pharmacokinetic data in rats for one carboxamide analogue demonstrated oral bioavailability and reasonable in vivo clearance.

  DOI：

  10.1021/jm801404b
• 作为产物：
  描述：

  2,3-吡啶二羧酸酐 在 叠氮磷酸二苯酯 、 三乙胺 作用下， 以 甲醇 为溶剂， 反应 5.08h， 生成 3-(BOC-氨基)吡啶甲酸甲酯
  参考文献：
  名称：

  WO2006/106326

  摘要：

  公开号：

文献信息

• Discovery and Structural Optimization of Toddacoumalone Derivatives as Novel PDE4 Inhibitors for the Topical Treatment of Psoriasis
  作者：Zhendong Song、Yi-You Huang、Ke-Qiang Hou、Lu Liu、Feng Zhou、Yue Huang、Guohui Wan、Hai-Bin Luo、Xiao-Feng Xiong

  DOI：10.1021/acs.jmedchem.1c02058

  日期：2022.3.10

  abnormal skin plaques, and phosphodiesterase 4 (PDE4) is an effective target for the treatment of inflammatory diseases such as psoriasis. Toddacoumalone is a natural PDE4 inhibitor with moderate potency and imperfect drug-like properties. To discover novel and potent PDE4 inhibitors with considerable druggability, a series of toddacoumalone derivatives were designed and synthesized, leading to the compound

  银屑病是一种常见的免疫介导的皮肤病，表现为皮肤异常斑块，而磷酸二酯酶 4（PDE4）是治疗银屑病等炎症性疾病的有效靶点。Toddacoumalone 是一种天然 PDE4 抑制剂，具有中等效力和不完善的药物样特性。为了发现具有相当成药性的新型强效 PDE4 抑制剂，设计并合成了一系列托达香豆酮衍生物，得到化合物 (2 R ,4 S )-6-ethyl-2-(2-hydroxyethyl)-2,8-dimethyl -4-(2-methylprop-1-en-1-yl)-2,3,4,6-tetrahydro-5 H -pyrano[3,2 - c ][1,8]naphthyridin-5-one ( 33a ) 具有高抑制效力 (IC 50= 3.1 nM)、令人满意的选择性、良好的皮肤渗透性和良好表征的结合机制。令人鼓舞的是， 33a的局部给药在咪喹莫特诱导的银屑病小鼠模型中表现出显着的治疗效果。
• SUBSTITUTED HETEROCYCLES AND THEIR USE AS CHK1, PDK1 AND PAK INHIBITORS
  申请人：Daly Kevin

  公开号：US20090275570A1

  公开（公告）日：2009-11-05

  The invention relates to novel compounds of Formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds possess CHK1 kinase inhibitory activity, PDK1 inhibitory activity and Pak kinase inhibitory activity and are accordingly useful in the treatment and/or prophylaxis of cancer.

  本发明涉及新的化合物（I）及其药物组成物和使用方法。这些新的化合物具有CHK1激酶抑制活性，PDK1抑制活性和Pak激酶抑制活性，因此在癌症的治疗和/或预防中有用。
• [EN] INHIBITORS OF BRUTON'S TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE DE BRUTON
  申请人：PHARMACYCLICS LLC

  公开号：WO2016196776A3

  公开（公告）日：2017-01-05
• INHIBITORS OF BRUTON'S TYROSINE KINASE
  申请人：Pharmacyclics LLC

  公开号：EP3310776A2

  公开（公告）日：2018-04-25
• INHIBITORS OF BRUTONS TYROSINE KINASE
  申请人：Pharmacyclics LLC

  公开号：US20180305348A1

  公开（公告）日：2018-10-25

  Disclosed herein are reversible and irreversible inhibitors of Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are described, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.